Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Orexo AB banner

Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 13.4 SEK -2.47% Market Closed
Market Cap: kr470.7m
Write Note Create Alert Ask AI

Bankruptcy Probability

Orexo AB's probability of bankruptcy is 1.6%, pointing to a small but noticeable default risk. The solvency score is 47/100 — a warning sign of potential financial weakness.

We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.

Moderate
Probability of Bankruptcy

Financial Position

Cash & Short-Term Investments
+
3Y
+10%
5Y
-59%
10Y
+9%
Long-Term Investments
+
3Y
+20 267%
5Y
+8 629%
10Y
+4 992%
Debt
+
3Y
-99%
5Y
-99%
10Y
-99%

Solvency Ratios

Solvency Ratios Comparison
Orexo AB Competitors

Country Company Market Cap D/E D/A Interest
Coverage 		Altman
Z-Score 		Quick
Ratio 		Current
Ratio 		Cash
Ratio
SE
Orexo AB
STO:ORX
465.1m SEK
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Eli Lilly and Co
NYSE:LLY
1.1T USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Johnson & Johnson
NYSE:JNJ
622.9B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Merck & Co Inc
NYSE:MRK
355B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
CH
Roche Holding AG
OTC:RHHBF
338.6B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
CH
Novartis AG
SIX:NOVN
224.4B CHF
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
UK
AstraZeneca PLC
LSE:AZN
184.1B GBP
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
CA
Nuvo Pharmaceuticals Inc
TSX:MRV
317B CAD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Pfizer Inc
NYSE:PFE
160.3B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
124.3B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
No Stocks Found

Continue ORX Research

Summary
ORX intrinsic value, competitors valuation, and company profile.
DCF Valuation
ORX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ORX stock valuation using valuation multiples.
Wall St Estimates
ORX price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ORX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Orexo AB listings:
OTC • USD
ORXOF
 OTC • USD
ORXOY
 F • EUR
C5G
Discover More
Is Orexo AB at risk of bankruptcy?

Orexo AB's probability of bankruptcy is 1.6%, pointing to a small but noticeable default risk.

The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.

How much debt does Orexo AB have?

As of the latest report, Orexo AB has total debt of 2.8m SEK. This includes both short-term (0 SEK) and long-term (2.8m SEK) debt.

You can find a full breakdown on its Balance Sheet.

Back to Top
ALPHA SPREAD
Follow us
Join 359,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.